17 April 2018 - - US-based biotechnology company Frequency Therapeutics has appointed William W. Chin, M.D. to chief medical officer, the company said.
Previously, Chin was senior vice president, drug discovery and clinical investigation, at Eli Lilly, and executive vice president of scientific and regulatory affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA).
Prior to PhRMA, he was the executive dean for research, Bertarelli Professor of Translational Medical Science and Professor of Medicine at Harvard Medical School from 2010 to 2013.
Chin is a Harvard-trained endocrinologist and longstanding faculty member. He was chief of the genetics division in the Department of Medicine at Brigham and Women's Hospital, a Howard Hughes Medical Institute investigator, and Professor of Medicine at HMS.
Chin received his A.B. in Chemistry from Columbia University, and his M.D. from Harvard Medical School.
Frequency Therapeutics develops small molecule drugs to stimulate cells in the body to reverse biological deficits and restore healthy tissue.
Through the transitory activation of these cells, the company enables disease modification without the complexity of genetic engineering. Its breakthrough therapy uses a proprietary combination of small-molecule drugs that induce dormant progenitor cells to multiply and create new cells.